VANCOUVER, British Columbia, June 16, 2026
Optimi Health Corp. has announced the commercial production of two new standardized microdose psilocybin finished drug products, formulated at 1 mg and 2 mg dosages, for use by qualified and authorized clinical research organizations. The launch marks a significant advancement in the growing field of psychedelic medicine by providing researchers with validated, GMP-manufactured psilocybin products designed specifically for controlled clinical studies. As interest in psychedelic-assisted therapies continues to expand globally, the availability of consistent and precisely dosed microdose formulations is expected to help address one of the major challenges facing psychedelic research—variability in active ingredient concentrations found in naturally occurring mushroom products. The new dosage formats expand Optimi’s existing portfolio, which already includes a 5 mg psilocybin capsule currently prescribed for treatment-resistant depression in Australia under the country’s Authorized Prescriber Scheme.
Standardized Microdose Products Aim to Improve Clinical Research Quality
The introduction of Optimi’s 1 mg and 2 mg psilocybin capsules is intended to support scientific investigations into microdosing, a practice involving repeated administration of sub-perceptual psychedelic doses that do not produce the full hallucinogenic effects typically associated with psilocybin. Microdosing protocols such as the widely recognized Fadiman and Stamets schedules have attracted growing interest among researchers investigating potential applications in mental health, cognitive performance, mood disorders, and neurological conditions. However, many studies have historically relied on dried mushrooms with highly variable psilocybin concentrations, creating challenges for reproducibility and scientific validation.
Optimi’s newly launched products address this issue by delivering naturally derived psilocybin at validated and consistent dosages, enabling researchers to conduct controlled studies with improved precision and reliability. Company executives emphasized that the products combine the natural source material preferred by many researchers with pharmaceutical-grade manufacturing standards required for rigorous clinical investigation.
GMP Manufacturing Supports Global Psychedelic Medicine Development
Advertisement
A key differentiator of Optimi’s program is its vertically integrated manufacturing model. The company cultivates and harvests mushrooms, produces a full-spectrum mushroom extract as the active pharmaceutical ingredient (API), and completes formulation, encapsulation, packaging, and quality control processes within its wholly owned facility in Princeton, British Columbia. Every stage of production is conducted under Good Manufacturing Practice (GMP) conditions and supported by the company’s Health Canada Drug Establishment License (DEL). This comprehensive manufacturing approach ensures product consistency, traceability, and compliance with international pharmaceutical standards.
As regulatory agencies and research institutions increasingly require validated drug products for clinical trials, GMP-certified manufacturing capabilities are becoming essential for advancing psychedelic therapies through formal development pathways. Optimi’s ability to control the entire production process from cultivation to finished dosage form positions the company as a significant supplier within the evolving psychedelic pharmaceutical sector.
Expanding Access to Regulated Psychedelic Therapies Worldwide
The launch reflects broader momentum within the global psychedelic medicine industry, where growing clinical evidence is driving interest in psilocybin and MDMA-based therapies for conditions such as treatment-resistant depression, post-traumatic stress disorder, anxiety disorders, and other mental health indications. Optimi currently supplies finished psilocybin and MDMA drug products to regulated therapeutic and research programs internationally, supporting both patient access initiatives and clinical trial development. The company’s products are already prescribed under regulated pathways in Australia and are accessible in Canada through special access mechanisms.
By introducing standardized microdose formulations specifically designed for research applications, Optimi is further expanding the toolkit available to investigators studying the safety, efficacy, and therapeutic potential of psychedelic compounds. As demand for pharmaceutical-grade psychedelic products continues to increase, the company’s latest product launch reinforces the importance of standardized dosing, regulatory compliance, and GMP manufacturing in supporting the next generation of evidence-based psychedelic medicine.
Source: Optimi Health press release
